HIT-ID is a joint initiative starting operation in 2011 with the Universities of Southern Denmark and Kiel as the core network partner and a number of academic and industrial associated network partners (e.g. Ribotask A/S, Exiqon A/S, Norgenta GmbH, Medigate GmbH, European ScreeningPort GmbH). HiT-iD is financed by the INTERREG 4 A-program Syddanmark-Schleswig-K.E.R.N. with funds from The European Regional Development Fund.
More information is available on the HiT-iD Website:
The University of Kiel has built up an internationally competitive unit for so-called next-generation sequencing. This technique allows for determining the identity of each single chemical building block of all 20,000 human genes and is used for the identification of changes that might cause human disease, such as inflammatory disorders or cancer. At the Lundbeckfonden Center of Excellence in Nanomedicine NanoCAN at the University of Southern Denmark, a unique robot unit has been implemented that allows inactivating each of the 20,000 genes in human cells to explore, what their function is, to search for new drugs, and to produce biochips for accelerating these processes.
The goal of HIT-ID is to bundle two existing platforms in the area of frontline research in human disease to create an internationally competitive joint infrastructure. This is also economically reasonable, because the two regions now can profit from high-tech equipment on each side of the border without additional investments. Beyond that HIT-ID aims at providing a platform for the exchange of know-how and the development of new creative approaches to accelerate the discovery of novel starting points for improved drugs. Finally, in long-term a further intended benefit for patients is to shorten the time needed to develop new treatment strategies.
Concept of the German-Danish High-Technology Platform for Innovative Disease Research (HIT-ID). The cross-border initiative merges infrastructure and know-how in the area of next-generation sequencing (University of Kiel, Germany) with a robotic platform and biochip robots for genome-wide studies of gene functions on the Danish side (University of Southern Denmark, Odense). Through this joint venture, changes in human genes that are discovered in diseases can be tested for their relevance for disease in a highly efficient manner. Filtering out the relevant changes in turn might provide novel starting points for the design of individualized therapies that operate with increased efficacy and less side effects. The goal of HIT-ID is to develop the necessary workflows, to create and test new technologies, and to promote exchange of know-how in a creative environment with other network partners.